Jorge Reis-Filho, Chief of AI for Science Innovation, Enterprise AI Unit, AstraZeneca, shared a post on LinkedIn:
“Seven months ago, I had the unique privilege to start leading the AI and Data Science organization for Oncology Research and Development at AstraZeneca.
Since then, we have made significant strides in advancing the development and implementation of multimodal foundation models and AI agentic frameworks to deliver innovative AI-driven approaches for patient selection and clinical development.
Thank you, Susan Galbraith, for the opportunity to lead the ODSAI team during this transformational period. Moving forward, I am delighted to now expand my remit in a new role as the Chief of AI for Science Innovation, where I will spearhead the development and implementation of innovative, reusable AI solutions in both oncology and biopharma R&D.
AI continues to advance at an unprecedented pace, and there is a clear asymmetric opportunity to harness this compounding of technologies to derive biological and clinical insights that were previously inaccessible.
Throughout my tenure at AstraZeneca, I have worked with our teams to drive proofs of concept in oncology R&D, enabling AI to reshape how we work and how our biomarkers are developed and delivered, a great example being our very own Quantitative Continuous Scoring (QCS), which received Breakthrough Device Designation by the FDA in April.
Domain-specific super intelligence is well within reach and I am thrilled to help guide its application at AstraZeneca. By uniting the exceptional AI talent across our R&D footprint, we can further accelerate drug discovery and transform clinical development, maximizing the impact of these compounding technologies throughout biopharma and oncology at scale.
This opportunity to build an ecosystem of patient-centric, AI-driven scientific innovation across R&D is a true privilege. I am immensely grateful to Anne-Claire Gerbaldi for entrusting me with this new role, our teams at AstraZeneca for their commitment to science and our executive leadership for the confidence they have placed in me to lead this cross-therapeutic area function.
By applying frontier AI solutions to our key differentiator, our data, we can continue contributing at pace to the development of the next generation of therapies and regimens that have the potential to meaningfully improve patient outcomes.”
More posts featuring Jorge Reis-Filho.